|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Capitalization1 |
4 023 | 4 388 | 12 060 | 6 740 | - | - |
| Entreprise Value (EV)1 |
2 872 | 3 097 | 6 305 | 3 140 | 3 237 | 3 716 |
| P/E ratio |
-33,8x | -144x | 74,9x | -23,7x | -23,5x | -31,6x |
| Yield |
- | - | - | - | - | - |
| Capitalization / Revenue |
25,8x | 13,8x | 13,5x | 12,8x | 12,9x | 10,5x |
| EV / Revenue |
18,4x | 9,74x | 7,04x | 5,97x | 6,19x | 5,78x |
| EV / EBITDA |
-33,6x | -78,0x | 16,5x | -17,5x | -15,9x | -17,5x |
| Price to Book |
3,86x | 3,46x | 4,19x | 2,36x | 2,49x | 2,58x |
| Nbr of stocks (in thousands) |
50 937 | 54 465 | 64 667 | 65 341 | - | - |
| Reference price (EUR) |
79,0 | 80,6 | 187 | 103 | 103 | 103 |
| Last update |
02/22/2018 | 02/21/2019 | 02/20/2020 | 11/26/2020 | 11/26/2020 | 11/26/2020 |
|
1 EUR in Million Estimates
|
|
| Income Statement Evolution | |
|
|
|
| Annual Income Statement Data |
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Net sales1 |
156 | 318 | 896 | 526 | 523 | 643 |
| EBITDA1 |
-85,5 | -39,7 | 383 | -180 | -203 | -212 |
| Operating profit (EBIT)1 |
-89,8 | -44,8 | 370 | -229 | -293 | -231 |
| Operating Margin |
-57,6% | -14,1% | 41,3% | -43,4% | -56,1% | -35,9% |
| Pre-Tax Profit (EBT)1 |
-116 | -29,2 | 150 | -312 | -370 | -285 |
| Net income1 |
-116 | -29,3 | 150 | -316 | -360 | -284 |
| Net margin |
-74,2% | -9,22% | 16,7% | -60,1% | -68,9% | -44,2% |
| EPS2 |
-2,34 | -0,56 | 2,49 | -4,35 | -4,39 | -3,27 |
| Dividend per Share2 |
- | - | - | - | - | - |
| Last update |
02/22/2018 | 02/21/2019 | 02/20/2020 | 11/26/2020 | 11/26/2020 | 11/26/2020 |
|
1 EUR in Million 2 EUR Estimates
|
|
|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Net Debt1 |
- | - | - | - | - | - |
| Net Cash position1 |
1 151 | 1 291 | 5 755 | 3 599 | 3 503 | 3 024 |
| Leverage (Debt / EBITDA) |
13,5x | 32,5x | -15,0x | 20,0x | 17,2x | 14,3x |
| Free Cash Flow1 |
-152 | -153 | 3 186 | -507 | -497 | -356 |
| ROE (Net Profit / Equities) |
-13,1% | -2,63% | 16,2% | -7,56% | -8,76% | -9,59% |
| Shareholders' equity1 |
885 | 1 115 | 925 | 4 177 | 4 115 | 2 961 |
| ROA (Net Profit / Asset) |
- | -2,15% | 8,82% | -5,30% | -6,30% | -6,90% |
| Assets1 |
- | 1 365 | 1 698 | 5 960 | 5 722 | 4 115 |
| Book Value Per Share2 |
20,5 | 23,3 | 44,5 | 43,8 | 41,4 | 39,9 |
| Cash Flow per Share |
-2,97 | -2,73 | 53,4 | - | -2,71 | -2,87 |
| Capex1 |
5,31 | 10,4 | 22,4 | 25,0 | 19,9 | 19,7 |
| Capex / Sales |
3,41% | 3,27% | 2,50% | 4,75% | 3,81% | 3,06% |
| Last update |
02/22/2018 | 02/21/2019 | 02/20/2020 | 11/26/2020 | 11/26/2020 | 11/26/2020 |
|
1 EUR in Million 2 EUR Estimates
|
|
|
|
|
|
Financial data source
© 2020 S&P Global Market Intelligence
|
|
|
Gilead shares slide after FDA knocks back rheumatoid arthritis drug |
Capitalization (EUR) 6 739 907 852 Capitalization (USD) 8 055 345 825 Net sales (EUR) 895 600 000 Net sales (USD) 1 067 877 616 Sales / Employee (EUR) 636 532 Sales / Employee (USD) 758 975 Free-Float capitalization (EUR) 5 016 531 600 Free-Float capitalization (USD) 5 995 615 632 Avg. Exchange 20 sessions (EUR) 45 726 024 Avg. Exchange 20 sessions (USD) 54 521 882 Average Daily Capital Traded 0,68%
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Evolution Valeur d'Entreprise / EBITDA
|
Canada
Deutschland
France
Schweiz (DE)
United Kingdom
Report
